PMC5937977_01
Levels of BCR-ABL in patients with chronic myeloid leukaemia in accordance with pregnancy and breastfeeding periods. IM- imatinib, NIL- nilotinib, IFN- interferon alpha, CA- conceiving attempt, PR- pregnancy, BF -breastfeeding. NT- no treatment. Observation is shown with 3- month time intervals.
mjhid-10-1-e2018027f1.jpg
PMC5937977_03_mjhid-10-1-e2018027f1.jpg
f1-mjhid-10-1-e2018027
The patient restarted treatment with imatinib at a dose of 400 mg (Figure 1c). The patient was switched to nilotinib at a dose of 800 mg and the MMR was achieved in 3 months. (Figure 1d).
PMC5937977_02
Levels of BCR-ABL in patients with chronic myeloid leukaemia in accordance with pregnancy and breastfeeding periods. IM- imatinib, NIL- nilotinib, IFN- interferon alpha, CA- conceiving attempt, PR- pregnancy, BF -breastfeeding. NT- no treatment. Observation is shown with 3- month time intervals.
mjhid-10-1-e2018027f1.jpg
PMC5937977_03_mjhid-10-1-e2018027f1.jpg
f1-mjhid-10-1-e2018027
The patient restarted treatment with imatinib at a dose of 400 mg (Figure 1c). The patient was switched to nilotinib at a dose of 800 mg and the MMR was achieved in 3 months. (Figure 1d).
PMC5937977_03
Levels of BCR-ABL in patients with chronic myeloid leukaemia in accordance with pregnancy and breastfeeding periods. IM- imatinib, NIL- nilotinib, IFN- interferon alpha, CA- conceiving attempt, PR- pregnancy, BF -breastfeeding. NT- no treatment. Observation is shown with 3- month time intervals.
mjhid-10-1-e2018027f1.jpg
PMC5937977_03_mjhid-10-1-e2018027f1.jpg
f1-mjhid-10-1-e2018027
The patient restarted treatment with imatinib at a dose of 400 mg (Figure 1c). The patient was switched to nilotinib at a dose of 800 mg and the MMR was achieved in 3 months. (Figure 1d).